CK Life Sciences International Holdings (FRA:LSI) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
CK Life Sciences International Holdings had a gross margin of 27.93% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
CK Life Sciences International Holdings Gross Margin % Related Terms
CK Life Sciences International Holdings Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings Gross Margin % Chart
CK Life Sciences International Holdings Annual Data
FRA:LSI vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, CK Life Sciences International Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CK Life Sciences International Holdings Gross Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
CK Life Sciences International Holdings (FRA:LSI) has a Gross Margin % of 27.93% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on CK Life Sciences International Holdings and its competitors. This is near median its historical median of 30.79. Over the past decade, CK Life Sciences International Holdings' Gross Margin % has ranged from 28.47 to 34.15. According to the industry distribution chart, CK Life Sciences International Holdings ranks #567 out of 737 companies in the Biotechnology industry, placing it in the top 76.9%.
Is CK Life Sciences International Holdings' Gross Margin % too high?
CK Life Sciences International Holdings' current Gross Margin % of 27.93% is near median its 10-year median of 30.79. Over the past 10 years, this metric has ranged from a low of 28.47 to a high of 34.15. The Biotechnology industry median Gross Margin % is 60.92. CK Life Sciences International Holdings' value of 27.93% is 54.2% below this industry median. Based on the distribution chart, CK Life Sciences International Holdings ranks #567 out of 737 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CK Life Sciences International Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CK Life Sciences International Holdings ranks #567 out of 737 companies for Gross Margin %. This places CK Life Sciences International Holdings in the lower half of its industry. The industry median Gross Margin % is 60.92. CK Life Sciences International Holdings' value of 27.93% is 54.2% below this benchmark. Historically, CK Life Sciences International Holdings' own Gross Margin % has ranged from 28.47 to 34.15 over the past decade. While the company's 10-year median is 30.79 vs. the industry median of 60.92, CK Life Sciences International Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CK Life Sciences International Holdings's current Gross Margin % of 27.93% is 54.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on CK Life Sciences International Holdings and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CK Life Sciences International Holdings's current Gross Margin % is 27.93%, which is near median its own 10-year median of 30.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
CK Life Sciences International Holdings (FRA:LSI) has a current Gross Margin % of 27.93%. The stock's GF Value™ is €0.08, compared to a current price of €0.06 — trading 20% below its estimated fair value. The current Gross Margin % is 27.93%, which is near median its 10-year median of 30.79 and 54.2% below the Biotechnology industry median of 60.92. CK Life Sciences International Holdings' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For CK Life Sciences International Holdings (FRA:LSI), the current Gross Margin % is 27.93% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CK Life Sciences International Holdings (FRA:LSI) Overvalued in 2026?
Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued.
The current stock price of €0.06 is trading 20% below its estimated GF Value™ of €0.08.
Key valuation signals for FRA:LSI:
Gross Margin %: 27.93% (near median its 10-year median of 30.79)
GF Value™: €0.08 vs. price of €0.06 (20% below fair value)
Industry Position: 54.2% below the Biotechnology median (#567 of 737)
No single metric tells the full story. See the FRA:LSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CK Life Sciences International Holdings Business Description
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
34GF Score
Get the complete analysis for FRA:LSI
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LSI has been successfully added to your 
